产品资料

MedKoo Biosciences/Elvitegravir/314218/20g

Elvitegravir(EVG,formerlyGS-9137)isanintegraseinhibitorusedtotreatHIVinfection.ThedruggainedapprovalbytheU.S.FoodandDrugAdmiNISTrationonAugust27,2012foruseinadultpatientsstartingHIVtreatmentforthefirsttimeaspartofthefixeddosecombinationknownasStribild.AccordingtotheresultsofthephaseIIclinicaltrial,patientstakingonce-dailyelvitegravirboostedbyritonavirhadgreaterreductionsinviralloadafter24weekscomparedtoindividualsrandomizedtoreceivearitonavir-boostedproteaseinhibitor.(Source:http://en.wikipedia.org/wiki/Elvitegravir).

MedKooCat#:314218
Name:Elvitegravir
CAS#:697761-98-1
ChemicalFormula:C23H23ClFNO5
ExactMass:447.12488
MolecularWeight:447.88
ElementalAnalysis:C,61.68;H,5.18;Cl,7.92;F,4.24;N,3.13;O,17.86

Synonym:GS9137;GS9137;GS9137;EVG;Elvitegravir;brandname:Stribild.

IUPAC/ChemicalName:6-[(3-Chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylicacid

InChiKey:JUZYLCPPVHEVSV-LJQANCHMSA-N

InChiCode:InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1

SMILESCode:O=C(C1=CN([C@@H](C(C)C)CO)C2=C(C=C(CC3=CC=CC(Cl)=C3F)C(OC)=C2)C1=O)O

TechnicalData

Appearance:

Solidpowder

Purity:

>98%(orrefertotheCertificateofAnalysis)

ShippingCondition:

Shippedunderambienttemperatureasnon-hazardouschemical.ThisproductisstableenoughforafewweeksduringordinaryshippingandtimespentinCustoms.

StorageCondition:

Dry,darkandat0-4Cforshortterm(daystoweeks)or-20Cforlongterm(monthstoyears).

Solubility:

SolubleinDMSO.

ShelfLife:

>2yearsifstoredproperly

DrugFormulation:

ThisdrugmaybeformulatedinDMSO

StockSolutionStorage:

0-4Cforshortterm(daystoweeks),or-20Cforlongterm(months).

HarmonizedSystemCode:

293490

References

1:PandeyKK.CriticalappraisalofelvitegravirinthetreatmentofHIV-1/AIDS.HIVAIDS(Auckl).2014May16;6:81-90.eCollection2014.Review.PubMedPMID:24876793;PubMedCentralPMCID:PMC4037326.

2:TemesgenZ.Cobicistat-boostedelvitegravir-basedfixed-dosecombinationantiretroviraltherapyforHIVinfection.DrugsToday(Barc).2012Dec;48(12):765-71.doi:10.1358/dot.2012.48.12.1895682.Review.PubMedPMID:23243633.

3:OlinJL,SpoonerLM,KlibanovOM.Elvitegravir/cobicistat/emtricitABIne/tenofovirdisoproxilfumaratesingletabletforHIV-1infectiontreatment.AnnPharmacother.2012Dec;46(12):1671-7.doi:10.1345/aph.1R468.Epub2012Nov7.Review.PubMedPMID:23136357.

4:WillsT,VegaV.Elvitegravir:aonce-dailyinhibitorofHIV-1integrase.ExpertOpinInvestigDrugs.2012Mar;21(3):395-401.doi:10.1517/13543784.2012.658914.Epub2012Feb10.Review.PubMedPMID:22321026.

5:LampirisHW.Elvitegravir:aonce-daily,boosted,HIV-1integraseinhibitor.ExpertRevAntiInfectTher.2012Jan;10(1):13-20.doi:10.1586/eri.11.157.Review.PubMedPMID:22149610.

6:RamanathanS,MathiasAA,GermanP,KearneyBP.ClinicalpharmacokineticandpharmacodynamicprofileoftheHIVintegraseinhibitorelvitegravir.ClinPharmacokinet.2011Apr;50(4):229-44.doi:10.2165/11584570-000000000-00000.Review.PubMedPMID:21348537.

7:ShimuraK,KodamaEN.Elvitegravir:anewHIVintegraseinhibitor.AntivirChemChemother.2009Oct19;20(2):79-85.doi:10.3851/IMP1397.Review.PubMedPMID:19843978.

8:SerraoE,OddeS,RamkumarK,NeamatiN.Raltegravir,elvitegravir,andmetoogravir:thebirthof"me-too"HIV-1integraseinhibitors.Retrovirology.2009Mar5;6:25.doi:10.1186/1742-4690-6-25.Review.Erratumin:Retrovirology.2009;6:33.PubMedPMID:19265512;PubMedCentralPMCID:PMC2660292.

9:GrantP,ZolopaA.Integraseinhibitors:aclinicalreviewofraltegravirandelvitegravir.JHIVTher.2008Jun;13(2):36-9.Review.PubMedPMID:18953272.

对照品标准品，生物试剂盒，gibco胎牛血清，试剂采购网，中国试剂网，细胞因子试剂盒

MedKoo Biosciences/Elvitegravir/314218/20g

TechnicalData

References